患者在选择降血糖药物时值得关注的结果和属性:混合方法研究
Elizabeth H Golembiewski1, Andrea E Garcia Bautista1, Eric Polley2
1Knowledge and Evaluation Research (KER) Unit, Mayo Clinic, Rochester, MN.
概括
患有2型糖尿病的成年人优先考虑避免失明,死亡和心脏问题. 他们更喜欢降低葡萄糖的疗效,口服药物和更少的胃肠道副作用.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 2型糖尿病的管理需要有效的药物治疗.
- 患者的偏好显著影响治疗的坚持和结果.
- 了解患者的优先事项对于个性化糖尿病护理至关重要.
研究的目的:
- 为了确定2型糖尿病非胰岛素治疗成人的药物治疗偏好.
- 为了确定健康结果和药物属性的相对重要性.
- 为临床决策和治疗选择提供信息.
主要方法:
- 混合方法研究涉及40名参与者.
- 参与者对健康结果和药物属性进行了排名.
- 通过对排名进行上下文化来进行定性数据收集.
主要成果:
- 优先考虑的健康结果包括失明 (63%),死亡 (60%),心脏病发作 (48%) 和心力衰竭 (48%).
- 降糖功效是最重要的药物属性 (68%).
- 口服 (45%) 和缺乏胃肠道副作用 (38%) 也是关键偏好.
结论:
- 对2型糖尿病的以患者为中心的护理应解决诸如失明和心血管事件等重大健康问题.
- 药物治疗选择应优先考虑血糖控制,口服和胃肠道耐受性.
- 纳入患者的偏好可以提高治疗坚持和2型糖尿病的管理.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
186
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
186
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
168
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
168
Diabetes: Management and Pharmacotherapy
256
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
256
Oral Hypoglycemic Agents: Glinides
152
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
152
Oral Hypoglycemic Agents: Sulfonylureas
199
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
199
Dipeptidyl Peptidase 4 Inhibitors
180
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
180


